My bibliography
Save this item
The Markov Process in Medical Prognosis
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Visalakshi Jeyaseelan & Tunny Sebastian & Jeyaseelan Lakshmanan & Shrikant I Bangdiwala, 2016. "Longitudinal data analysis of mean passage time among malnutrition states: an application of Markov chains," Journal of Applied Statistics, Taylor & Francis Journals, vol. 43(15), pages 2729-2739, November.
- Bruce A. Craig & Peter P. Sendi, 2002. "Estimation of the transition matrix of a discrete‐time Markov chain," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 33-42, January.
- Rowan Iskandar, 2018. "A theoretical foundation for state-transition cohort models in health decision analysis," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-11, December.
- Xudong Du & Mier Li & Ping Zhu & Ju Wang & Lisha Hou & Jijie Li & Hongdao Meng & Muke Zhou & Cairong Zhu, 2018. "Comparison of the flexible parametric survival model and Cox model in estimating Markov transition probabilities using real-world data," PLOS ONE, Public Library of Science, vol. 13(8), pages 1-13, August.
- Felicitas Kuehne & Ursula Rochau & Noman Paracha & Jennifer M. Yeh & Eduardo Sabate & Uwe Siebert, 2022. "Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling," Medical Decision Making, , vol. 42(2), pages 194-207, February.
- Franck Maunoury & Christian Farinetto & Stéphane Ruckly & Jeremy Guenezan & Jean-Christophe Lucet & Alain Lepape & Julien Pascal & Bertrand Souweine & Olivier Mimoz & Jean-François Timsit, 2018. "Cost-effectiveness analysis of chlorhexidine-alcohol versus povidone iodine-alcohol solution in the prevention of intravascular-catheter-related bloodstream infections in France," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-16, May.
- Uwe Siebert & Gaby Sroczynski & Jürgen Wasem & Wolfgang Greiner & Ulrike Ravens-Sieberer & Pamela Aidelsburger & Bärbel Kurth & Monika Bullinger & J.-Matthias Schulenburg & John Wong & Siegbert Rossol, 2005. "Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 112-123, June.
- Gerardo Machnicki & Jean-Francois Ricci & Daniel Brennan & Mark Schnitzler, 2008. "Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients," PharmacoEconomics, Springer, vol. 26(11), pages 951-967, November.
- Paul J. Roach & Craig Fleming & Michael D. Hagen & Stephen G. Pauker, 1988. "Prostatic Cancer in a Patient with Asymptomatic HIV Infection," Medical Decision Making, , vol. 8(2), pages 132-144, June.
- Dennis A. Plante & Seymour Zimbler & Stephen G. Pauker, 1984. "A Ten-Year-Old Boy with Cerebral Palsy and Femoral Anteversion," Medical Decision Making, , vol. 4(2), pages 229-247, June.
- Craig Fleming & John B. Wong & Alan J. Moskowitz & Stephen G. Pauker, 1988. "A Peripartum Neurologic Event: Shooting from the Hip," Medical Decision Making, , vol. 8(1), pages 55-71, February.
- Karina Hansen & Christophe Lançon & Mondher Toumi, 2006. "Pharmacoeconomic modelling in schizophrenia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(1), pages 19-29, March.
- C. Kent Kwoh & J. Robert Beck & Stephen G. Pauker, 1984. "Repeated Syncope with Negative Diagnostic Evaluation," Medical Decision Making, , vol. 4(3), pages 351-377, August.
- Manouchehr Tavakoli & Neil Pumford & Mark Woodward & Alex Doney & John Chalmers & Stephen MacMahon & Ronald MacWalter, 2009. "An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 111-119, February.
- Gordon B. Hazen, 2022. "Augmenting Markov Cohort Analysis to Compute (Co)Variances: Implications for Strength of Cost-Effectiveness," INFORMS Journal on Computing, INFORMS, vol. 34(6), pages 3170-3180, November.
- Steven M. Shechter & Matthew D. Bailey & Andrew J. Schaefer & Mark S. Roberts, 2008. "The Optimal Time to Initiate HIV Therapy Under Ordered Health States," Operations Research, INFORMS, vol. 56(1), pages 20-33, February.
- Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt, 2014. "Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 133-142, March.
- Uwe Siebert, 2003. "When should decision-analytic modeling be used in the economic evaluation of health care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 143-150, September.
- Aslam Anis & Huiying Sun & Sonia Singh & John Woolcott & Bohdan Nosyk & Marc Brisson, 2006. "A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy," PharmacoEconomics, Springer, vol. 24(4), pages 387-400, April.
- Roy Lothan & Noa Gutman & Dan Yamin, 2022. "Country versus pharmaceutical company interests for hepatitis C treatment," Health Care Management Science, Springer, vol. 25(4), pages 725-749, December.
- Fernando Alarid-Escudero & Eline Krijkamp & Eva A. Enns & Alan Yang & M. G. Myriam Hunink & Petros Pechlivanoglou & Hawre Jalal, 2023. "An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example," Medical Decision Making, , vol. 43(1), pages 3-20, January.
- Rudzītis Normunds & Čevers Aldis, 2015. "Development of Customs Fiscal Function in Latvia," Acta Universitatis Sapientiae, Economics and Business, Sciendo, vol. 27(1), pages 23-28, December.
- Franck Maunoury & Anastasiia Motrunich & Maria Palka-Santini & Stéphanie F Bernatchez & Stéphane Ruckly & Jean-François Timsit, 2015. "Cost-Effectiveness Analysis of a Transparent Antimicrobial Dressing for Managing Central Venous and Arterial Catheters in Intensive Care Units," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-14, June.
- Beate Jahn & Sarah Friedrich & Joachim Behnke & Joachim Engel & Ursula Garczarek & Ralf Münnich & Markus Pauly & Adalbert Wilhelm & Olaf Wolkenhauer & Markus Zwick & Uwe Siebert & Tim Friede, 2022. "On the role of data, statistics and decisions in a pandemic," AStA Advances in Statistical Analysis, Springer;German Statistical Society, vol. 106(3), pages 349-382, September.
- Dominique Bureau & Geneviève Plu-Bureau & Jean-Christophe Thalabard, 1993. "L'évaluation économique des traitements médicaux : méthodes et enjeux," Économie et Statistique, Programme National Persée, vol. 266(1), pages 65-75.
- John B. Wong & Robert K. Webb & Stephen G. Pauker, 1987. "Double Trouble," Medical Decision Making, , vol. 7(3), pages 174-193, August.
- Donna M. Edwards & Ross D. Shachter & Douglas K. Owens, 1998. "A Dynamic HIV-Transmission Model for Evaluating the Costs and Benefits of Vaccine Programs," Interfaces, INFORMS, vol. 28(3), pages 144-166, June.
- David G. Simon, 1986. "A Cost-effectiveness Analysis of Cyclosporine in Cadaveric Kidney Transplantation," Medical Decision Making, , vol. 6(4), pages 199-207, December.
- Lukas J.A. Stalpers & Hans J.M. Van Gasteren & Willem A.J. Van Daal, 1989. "DEALE-ing with Life Expectancy and Mortality Rates," Medical Decision Making, , vol. 9(2), pages 150-152, June.
- de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.